PLA2R1
Basic information
Region (hg38): 2:159932006-160062615
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PLA2R1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 62 | 73 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 64 | 12 | 5 |
Variants in PLA2R1
This is a list of pathogenic ClinVar variants found in the PLA2R1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-159941788-C-G | not specified | Uncertain significance (Sep 26, 2023) | ||
2-159941801-C-T | not specified | Uncertain significance (Jun 03, 2024) | ||
2-159941866-C-T | not specified | Likely benign (Jun 07, 2024) | ||
2-159942156-A-C | not specified | Uncertain significance (Nov 18, 2022) | ||
2-159944947-G-A | not specified | Uncertain significance (Jul 13, 2021) | ||
2-159944996-G-A | not specified | Uncertain significance (Dec 12, 2023) | ||
2-159945014-T-C | not specified | Uncertain significance (Feb 03, 2022) | ||
2-159945031-C-A | not specified | Uncertain significance (Apr 26, 2023) | ||
2-159945073-A-G | not specified | Uncertain significance (Nov 10, 2022) | ||
2-159945074-T-G | not specified | Uncertain significance (Apr 22, 2022) | ||
2-159946906-AAAGAT-A | Kidney disorder | Uncertain significance (Feb 01, 2018) | ||
2-159949647-C-T | not specified | Uncertain significance (Dec 09, 2023) | ||
2-159949672-G-A | Likely benign (Sep 01, 2022) | |||
2-159949689-C-T | not specified | Uncertain significance (Jul 09, 2021) | ||
2-159949706-G-A | not specified | Uncertain significance (Apr 12, 2022) | ||
2-159949706-G-C | not specified | Uncertain significance (Jan 27, 2022) | ||
2-159949714-C-A | not specified | Likely benign (May 20, 2024) | ||
2-159949747-G-A | Kidney disorder | Uncertain significance (Dec 12, 2016) | ||
2-159951444-T-C | not specified | Uncertain significance (Jun 26, 2023) | ||
2-159951479-G-C | not specified | Uncertain significance (May 31, 2023) | ||
2-159951564-C-T | Atypical hemolytic-uremic syndrome | Benign (Oct 05, 2022) | ||
2-159951566-T-C | not specified | Likely benign (Dec 13, 2022) | ||
2-159955228-C-T | not specified | Uncertain significance (Mar 24, 2023) | ||
2-159955235-T-C | not specified | Uncertain significance (Nov 17, 2023) | ||
2-159955784-T-C | not specified | Uncertain significance (Aug 08, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PLA2R1 | protein_coding | protein_coding | ENST00000283243 | 30 | 130603 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.23e-30 | 0.654 | 122849 | 78 | 2821 | 125748 | 0.0116 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.351 | 748 | 775 | 0.965 | 0.0000394 | 9724 |
Missense in Polyphen | 241 | 271.33 | 0.88822 | 3606 | ||
Synonymous | 0.394 | 263 | 271 | 0.970 | 0.0000144 | 2564 |
Loss of Function | 2.57 | 60 | 85.7 | 0.700 | 0.00000400 | 1012 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.119 | 0.118 |
Ashkenazi Jewish | 0.0484 | 0.0484 |
East Asian | 0.000666 | 0.000653 |
Finnish | 0.00106 | 0.00106 |
European (Non-Finnish) | 0.00249 | 0.00246 |
Middle Eastern | 0.000666 | 0.000653 |
South Asian | 0.00250 | 0.00249 |
Other | 0.0120 | 0.0118 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for secretory phospholipase A2 (sPLA2). Acts as a receptor for phosholipase sPLA2-IB/PLA2G1B but not sPLA2- IIA/PLA2G2A. Also able to bind to snake PA2-like toxins. Although its precise function remains unclear, binding of sPLA2 to its receptor participates in both positive and negative regulation of sPLA2 functions as well as clearance of sPLA2. Binding of sPLA2- IB/PLA2G1B induces various effects depending on the cell type, such as activation of the mitogen-activated protein kinase (MAPK) cascade to induce cell proliferation, the production of lipid mediators, selective release of arachidonic acid in bone marrow- derived mast cells. In neutrophils, binding of sPLA2-IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell adhesion. May be involved in responses in proinflammatory cytokine productions during endotoxic shock. Also has endocytic properties and rapidly internalizes sPLA2 ligands, which is particularly important for the clearance of extracellular sPLA2s to protect their potent enzymatic activities. The soluble secretory phospholipase A2 receptor form is circulating and acts as a negative regulator of sPLA2 functions by blocking the biological functions of sPLA2-IB/PLA2G1B. {ECO:0000269|PubMed:15611272, ECO:0000269|PubMed:7721806}.;
- Pathway
- Phagosome - Homo sapiens (human);Tuberculosis - Homo sapiens (human);Acyl chain remodelling of PI;Acyl chain remodelling of PG;Metabolism of lipids;Metabolism;Acyl chain remodelling of PC;Acyl chain remodelling of PS;Glycerophospholipid biosynthesis;Phospholipid metabolism;Acyl chain remodelling of PE;Synthesis of PA
(Consensus)
Recessive Scores
- pRec
- 0.118
Intolerance Scores
- loftool
- 0.999
- rvis_EVS
- 0.86
- rvis_percentile_EVS
- 88.64
Haploinsufficiency Scores
- pHI
- 0.149
- hipred
- N
- hipred_score
- 0.399
- ghis
- 0.486
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.157
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pla2r1
- Phenotype
- immune system phenotype;
Gene ontology
- Biological process
- cytokine production;receptor-mediated endocytosis;positive regulation of DNA damage response, signal transduction by p53 class mediator;reactive oxygen species metabolic process;positive regulation of arachidonic acid secretion;replicative senescence;oxidative stress-induced premature senescence;negative regulation of phospholipase A2 activity;negative regulation of arachidonic acid secretion
- Cellular component
- extracellular region;plasma membrane;cell surface;integral component of membrane;receptor complex
- Molecular function
- transmembrane signaling receptor activity;carbohydrate binding;phospholipase binding